The UK and US have signed a key trade agreement that will guarantee no tariffs on UK drug products going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that tariffs on these key products will stay at nothing for a period of the next three years.
This development comes after earlier threats to hike tariffs on branded drug products, with increases discussed reaching one hundred percent.
"This agreement between the United Kingdom bolsters the international landscape for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," an announcement said.
Economic Impact
Medicines represent one of the UK's largest goods shipped to the US, which is easily the biggest buyer for large UK drugmakers.
Trade data indicate that in the 12 months leading up to last September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a minister remarked.
Detailed British Pledges
The pact entails several notable pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments topped twenty percent.
Broader Context
The pact comes amid a long-running tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were intensified by arguments that American customers were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while major investments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
